| Name | Title | Contact Details |
|---|
Planmeca USA is a subsidiary of Planmeca, the largest privately held company in the dental equipment market and one of the industry`s leading manufacturers of dental X-rays and core equipment. With a North American office located in Hoffman Estates, Illinois, and international headquarters in Helsinki, Finland, Planmeca is well established in high-tech dental markets and currently serves 120 countries worldwide.
MedaPhase is a San Antonio, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
ValenTx was founded with the goal of treating some of the most pervasive health problems of our time: obesity and obesity-related metabolic disorders such as type-2 diabetes and hypertension. Our approach is to create a non-surgical, endoluminal bypass device that builds on the success of established medical interventions, resulting in a highly effective and least-invasive therapy. Current treatments for these diseases include surgery, pharmacology, and medically supervised lifestyle management. The risks, costs, and in some cases poor efficacy of these treatments have hampered their broad adoption by patients, physicians, and payers alike. A truly unmet clinical need exists for a therapy that can deliver the efficacy obtained through surgery, but without the risks and costs associated with surgical intervention. The ValenTx endoluminal bypass therapy mimics the attributes of a Roux-en-Y gastric bypass and is implanted through a non-surgical, endoscopic procedure. This procedure does not require gastric stapling or permanent changes to the patient`s anatomy. The device is removable, replaceable and designed so that the physician could change the therapeutic profile, thereby optimizing the treatment towards the individual patient`s needs. ValenTx has developed a strong intellectual property portfolio, which lies at the foundation of this therapy. The company has successfully conducted a series of clinical studies demonstrating the viability, safety, and efficacy of the therapy.
Urologix, Inc., based in Minneapolis, develops, manufactures, markets and distributes minimally invasive medical products for the treatment of obstruction and symptoms due to Benign Prostatic Hyperplasia (BPH). Urologix`s Cooled ThermoTherapy™ produces targeted microwave energy combined with a unique cooling mechanism to protect healthy tissue and enhance patient comfort. The Prostiva® RF Therapy System delivers radio frequency energy directly into the prostate, destroying prostate tissue, reducing constriction of the urethra, and thereby relieving BPH symptoms. Both therapies provide safe, effective and lasting relief of the symptoms and obstruction due to BPH. Prostiva is a registered trademark of Medtronic, Inc., used under license. All other trademarks are the property of Urologix.
MediGroup is a Saint Charles, MO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.